Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | GCGR | P47871 | 1/20 | 0.43 |
| ▸ | GIPR | P48546 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | IDE | P14735 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GCG | P01275 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035185 | 0.95 | GCGR (0.42) | CTSSGCGRGIPRFFAR1FFAR4 | |
| SCHEMBL6036208 | 0.92 | DGAT1 (0.41) | CTSSGCGRGIPREGLN1MCHR1 | |
| SCHEMBL6036340 | 0.87 | DGAT1 (0.40) | GCGRGIPREGLN1MCHR1FAAH | |
| SCHEMBL6035773 | 0.80 | PTGDR2 (0.38) | GCGRGIPRSMN1; SMN2GCG | |
| SCHEMBL6035872 | 0.78 | PPARA (0.41) | GCGRFFAR1FFAR4EGLN1IDE | |
| SCHEMBL6036337 | 0.78 | PTGDR2 (0.42) | GCGRGIPRFFAR1FFAR4 | |
| SCHEMBL6035517 | 0.76 | FFAR4 (0.38) | GCGRFFAR1FFAR4EGLN1IDE | |
| SCHEMBL6034677 | 0.76 | LTB4R (0.40) | GCGRFFAR1FFAR4EGLN1IDE | |
| SCHEMBL6036233 | 0.76 | GCGR (0.38) | GCGRGIPRGCG | |
| SCHEMBL6036002 | 0.76 | NR1H2 (0.45) | EGLN1IDESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | CTSS 4057/4885GCGR 93/4885GIPR 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.